225 related articles for article (PubMed ID: 32072438)
1. Covalent Versus Non-covalent Enzyme Inhibition: Which Route Should We Take? A Justification of the Good and Bad from Molecular Modelling Perspective.
Aljoundi A; Bjij I; El Rashedy A; Soliman MES
Protein J; 2020 Apr; 39(2):97-105. PubMed ID: 32072438
[TBL] [Abstract][Full Text] [Related]
2. Theory and applications of covalent docking in drug discovery: merits and pitfalls.
Kumalo HM; Bhakat S; Soliman ME
Molecules; 2015 Jan; 20(2):1984-2000. PubMed ID: 25633330
[TBL] [Abstract][Full Text] [Related]
3. Toward Atomistic Modeling of Irreversible Covalent Inhibitor Binding Kinetics.
Yu HS; Gao C; Lupyan D; Wu Y; Kimura T; Wu C; Jacobson L; Harder E; Abel R; Wang L
J Chem Inf Model; 2019 Sep; 59(9):3955-3967. PubMed ID: 31425654
[TBL] [Abstract][Full Text] [Related]
4. Tracing Potential Covalent Inhibitors of an E3 Ubiquitin Ligase through Target-Focused Modelling.
Bjij I; Ramharack P; Khan S; Cherqaoui D; Soliman MES
Molecules; 2019 Aug; 24(17):. PubMed ID: 31466292
[TBL] [Abstract][Full Text] [Related]
5. The expanding repertoire of covalent warheads for drug discovery.
Mehta NV; Degani MS
Drug Discov Today; 2023 Dec; 28(12):103799. PubMed ID: 37839776
[TBL] [Abstract][Full Text] [Related]
6. Expanding the Armory: Predicting and Tuning Covalent Warhead Reactivity.
Lonsdale R; Burgess J; Colclough N; Davies NL; Lenz EM; Orton AL; Ward RA
J Chem Inf Model; 2017 Dec; 57(12):3124-3137. PubMed ID: 29131621
[TBL] [Abstract][Full Text] [Related]
7. [Research progress of the small molecule covalent inhibitors].
Yang B; Wang WJ; Li LL
Yao Xue Xue Bao; 2014 Feb; 49(2):158-65. PubMed ID: 24761604
[TBL] [Abstract][Full Text] [Related]
8. Assessment of Tractable Cysteines for Covalent Targeting by Screening Covalent Fragments.
Petri L; Ábrányi-Balogh P; Tímea I; Pálfy G; Perczel A; Knez D; Hrast M; Gobec M; Sosič I; Nyíri K; Vértessy BG; Jänsch N; Desczyk C; Meyer-Almes FJ; Ogris I; Golič Grdadolnik S; Iacovino LG; Binda C; Gobec S; Keserű GM
Chembiochem; 2021 Feb; 22(4):743-753. PubMed ID: 33030752
[TBL] [Abstract][Full Text] [Related]
9. Electrophilic warheads in covalent drug discovery: an overview.
Péczka N; Orgován Z; Ábrányi-Balogh P; Keserű GM
Expert Opin Drug Discov; 2022 Apr; 17(4):413-422. PubMed ID: 35129005
[TBL] [Abstract][Full Text] [Related]
10. Covalent inhibitors design and discovery.
De Cesco S; Kurian J; Dufresne C; Mittermaier AK; Moitessier N
Eur J Med Chem; 2017 Sep; 138():96-114. PubMed ID: 28651155
[TBL] [Abstract][Full Text] [Related]
11. Affinity and Selectivity Assessment of Covalent Inhibitors by Free Energy Calculations.
Mihalovits LM; Ferenczy GG; Keserű GM
J Chem Inf Model; 2020 Dec; 60(12):6579-6594. PubMed ID: 33295760
[TBL] [Abstract][Full Text] [Related]
12. Approaches to mitigate the risk of serious adverse reactions in covalent drug design.
Baillie TA
Expert Opin Drug Discov; 2021 Mar; 16(3):275-287. PubMed ID: 33006907
[TBL] [Abstract][Full Text] [Related]
13. Drug discovery for a new generation of covalent drugs.
Kalgutkar AS; Dalvie DK
Expert Opin Drug Discov; 2012 Jul; 7(7):561-81. PubMed ID: 22607458
[TBL] [Abstract][Full Text] [Related]
14. Identification of Highly Selective Lipoprotein-Associated Phospholipase A2 (Lp-PLA2) Inhibitors by a Covalent Fragment-Based Approach.
Huang F; Hu H; Wang K; Peng C; Xu W; Zhang Y; Gao J; Liu Y; Zhou H; Huang R; Li M; Shen J; Xu Y
J Med Chem; 2020 Jul; 63(13):7052-7065. PubMed ID: 32459096
[TBL] [Abstract][Full Text] [Related]
15. Emerging and Re-Emerging Warheads for Targeted Covalent Inhibitors: Applications in Medicinal Chemistry and Chemical Biology.
Gehringer M; Laufer SA
J Med Chem; 2019 Jun; 62(12):5673-5724. PubMed ID: 30565923
[TBL] [Abstract][Full Text] [Related]
16. An update on the discovery and development of reversible covalent inhibitors.
Faridoon ; Ng R; Zhang G; Li JJ
Med Chem Res; 2023; 32(6):1039-1062. PubMed ID: 37305209
[TBL] [Abstract][Full Text] [Related]
17. Covalent Inhibition in Drug Discovery: Filling the Void in Literature.
Bjij I; Olotu FA; Agoni C; Adeniji E; Khan S; El Rashedy A; Cherqaoui D; Soliman MES
Curr Top Med Chem; 2018; 18(13):1135-1145. PubMed ID: 30068277
[TBL] [Abstract][Full Text] [Related]
18. A Perspective on the Kinetics of Covalent and Irreversible Inhibition.
Strelow JM
SLAS Discov; 2017 Jan; 22(1):3-20. PubMed ID: 27703080
[TBL] [Abstract][Full Text] [Related]
19. Strategies for discovering and derisking covalent, irreversible enzyme inhibitors.
Johnson DS; Weerapana E; Cravatt BF
Future Med Chem; 2010 Jun; 2(6):949-64. PubMed ID: 20640225
[TBL] [Abstract][Full Text] [Related]
20. Characterising covalent warhead reactivity.
Martin JS; MacKenzie CJ; Fletcher D; Gilbert IH
Bioorg Med Chem; 2019 May; 27(10):2066-2074. PubMed ID: 30975501
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
